Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
Uranium Prices Could Top $100 as Nuclear Demand Grows 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Oil Prices Slip as Trump Eases Iran Supply Fears 
Japan, US Target AI and Chips in $550 Billion Investment Push 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Oil Prices Surge as U.S.-Iran Conflict Threatens Hormuz Supply 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
European Stocks Edge Higher as Bond Yields Ease 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
OPEC+ Expected to Hold October Oil Output Steady 
Asian Stocks Rise as Bond Yields Ease, Oil Prices Stabilize 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
